Abigail was diagnosed with Juvenile Dermatomyositis in August 2017 at the age of 12. Juvenile Dermatomyositis is rare autoimmune disease that can affect virtually any system of the body, the heart, lungs, skin, muscles, and more, and can be life-threatening. There are currently no FDA-approved treatments and no cure. At the time of diagnosis Abigail had deteriorated to the point of having difficulty breathing, eating, dressing, and bathing. She had lost her mobility and was wheelchair bound. Her decline happened so quickly and was so aggressive, it was not evident that it could be stopped. Abigail was admitted to Boston Children’s hospital and spent five days receiving aggressive intravenous treatments. A cocktail of Chemotherapy, large doses of steroids, and immunoglobulin were pumped into her body. While the response was not immediate, within a few weeks it was evident that she was no longer declining. It has now been 18 months and Abigail continues to recover. Her treatment consists of daily steroids, weekly chemotherapy shots, and infusions every third week. She has responded well to treatment, however the drugs used to put this disease into remission have taken their toll on her body with the development of osteoporosis and cataracts. If all goes well, she will be off steroids in a couple of months but will continue with chemo and infusions for 2-3 more years. We pray that the disease stays in remission for the rest of her life. The Cure JM Foundation is the global leader in Juvenile Myositis research. Thanks to friends and family like you, this year Cure JM has made extraordinary progress toward its mission to find better treatments and a cure for Juvenile Myositis. Cure JM’s Strategic Research Plan calls for substantial new investments to identify the genes that cause Juvenile Myositis and to understand their role. The plan calls for investments in drug discovery and development so children will have more and better treatments. And the plan calls for speeding basic research out of the lab and into the clinic through partnerships with pharmaceutical companies that will be needed to bring new treatments for Juvenile Myositis to the marketplace. Accomplishing these research goals is within our grasp, and Cure JM’s determination to succeed is unwavering, but today, Cure JM needs your financial support more than ever. Like most rare diseases, Juvenile Myositis research funding is almost entirely from grassroots efforts by families, and every single dollar raised makes a difference. One reason that Cure JM is a top-rated charity is because 87% of revenues go directly to research and programs to support its important mission. Thank you so, so much. Your support gives our family the hope and strength needed to keep on fighting. Please "Share" this with your network to help Team Abigail achieve its goal!